Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates.
Paclitaxel (1a), a well known antitumor agent adopted mainly for the treatment of breast and ovarian cancer, suffers from significant disadvantages such as low solubility, certain toxicity and specific drug-resistance of some tumor cells. To overcome these problems extensive research has been carried out. Among the various proposed strategies, the conjugation of paclitaxel (1a) to a biocompatible polymer, such as hyaluronic acid (HA, 2), has also been considered. Coupling a bioactive compound to a biocompatible polymer offers, in general, many advantages such as better drug solubilization, better stabilization, specific localization and controlled release. Hereafter the design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates are reviewed. An overview of HA-paclitaxel combinations is also given.
Leonelli
Francesca
F
Dipartimento di Chimica and Istituto di Chimica Biomolecolare del CNR, Sezione di Roma, Università degli Studi di Roma La Sapienza, P.le Aldo Moro 5, BOX n. 34 ROMA 62, I-00185 Roma, Italy. francesca.leonelli@uniroma1.it
La Bella
Angela
A
Migneco
Luisa Maria
LM
Bettolo
Rinaldo Marini
RM
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000138:chemical synthesis*; D000971:Antineoplastic Combined Chemotherapy Protocols; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D006820:Hyaluronic Acid / Q000138:chemical synthesis* / Q000737:chemistry; D017239:Paclitaxel / Q000138:chemical synthesis* / Q000737:chemistry
D000972:Antineoplastic Agents, Phytogenic; D006820:Hyaluronic Acid; D017239:Paclitaxel